{"protocolSection": {"identificationModule": {"nctId": "NCT01079130", "orgStudyIdInfo": {"id": "CQAB149B2357"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of Different Doses of Indacaterol", "officialTitle": "A Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Different Doses of Indacaterol in Adult Patients With Persistent Asthma, Using Salmeterol as an Active Control"}, "statusModule": {"statusVerifiedDate": "2011-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-02"}, "primaryCompletionDateStruct": {"date": "2010-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-03-01", "studyFirstSubmitQcDate": "2010-03-01", "studyFirstPostDateStruct": {"date": "2010-03-02", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-07-22", "resultsFirstSubmitQcDate": "2011-07-22", "resultsFirstPostDateStruct": {"date": "2011-08-19", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-07-22", "lastUpdatePostDateStruct": {"date": "2011-08-19", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External Affairs", "oldOrganization": "Novartis Pharmaceuticals"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This study compared the 14-day bronchodilator efficacy of indacaterol with that of placebo and salmeterol"}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Indacaterol", "asthma", "salmeterol"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 511, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Indacaterol 18.75 \u00b5g", "type": "EXPERIMENTAL", "description": "Indacaterol 18.75 \u00b5g once daily in the morning via Concept1, a single-dose dry powder inhaler (SDDPI) and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, a multi-dose dry powder inhaler (MDDPI) for 2 weeks.\n\nDaily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study.", "interventionNames": ["Drug: Indacaterol", "Drug: Placebo to Salmeterol"]}, {"label": "Indacaterol 37.5 \u00b5g", "type": "EXPERIMENTAL", "description": "Indacaterol 37.5 \u00b5g once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, a MDDPI for 2 weeks.\n\nDaily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study.", "interventionNames": ["Drug: Indacaterol", "Drug: Placebo to Salmeterol"]}, {"label": "Indacaterol 75 \u00b5g", "type": "EXPERIMENTAL", "description": "Indacaterol 75 \u00b5g once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, a MDDPI for 2 weeks.\n\nDaily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study.", "interventionNames": ["Drug: Indacaterol", "Drug: Placebo to Salmeterol"]}, {"label": "Indacaterol 150 \u00b5g", "type": "EXPERIMENTAL", "description": "Indacaterol 150 \u00b5g once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, MDDPI for 2 weeks.\n\nDaily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study.", "interventionNames": ["Drug: Indacaterol", "Drug: Placebo to Salmeterol"]}, {"label": "Salmeterol", "type": "ACTIVE_COMPARATOR", "description": "Salmeterol 50 \u00b5g twice daily in the morning and in the evening via Diskus\u00ae, a multi-dose dry powder inhaler (MDDPI) and Placebo to Indacaterol once daily in the morning via Concept1, a SDDPI for 2 weeks.\n\nDaily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study.", "interventionNames": ["Drug: Salmeterol", "Drug: Placebo to Indacaterol"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo to Indacaterol once daily in the morning via Concept 1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, a MDDPI for 2 weeks.\n\nDaily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study.", "interventionNames": ["Drug: Placebo to Indacaterol", "Drug: Placebo to Salmeterol"]}], "interventions": [{"type": "DRUG", "name": "Indacaterol", "description": "Once daily via Concept1, a single-dose dry powder inhaler (SDDPI) for two week. Dosage varies according to randomization scheme.", "armGroupLabels": ["Indacaterol 150 \u00b5g", "Indacaterol 18.75 \u00b5g", "Indacaterol 37.5 \u00b5g", "Indacaterol 75 \u00b5g"]}, {"type": "DRUG", "name": "Salmeterol", "description": "50 \u00b5g Salmeterol twice daily in the morning and in the evening via Diskus\u00ae, a MDDPI for 2 weeks.", "armGroupLabels": ["Salmeterol"]}, {"type": "DRUG", "name": "Placebo to Indacaterol", "description": "Placebo to Indacaterol once daily in the morning via Concept 1, a SDDPI.", "armGroupLabels": ["Placebo", "Salmeterol"]}, {"type": "DRUG", "name": "Placebo to Salmeterol", "description": "Placebo to Salmeterol twice daily in the morning and in the evening via Diskus\u00ae, a multi-dose dry powder inhaler (MDDPI).", "armGroupLabels": ["Indacaterol 150 \u00b5g", "Indacaterol 18.75 \u00b5g", "Indacaterol 37.5 \u00b5g", "Indacaterol 75 \u00b5g", "Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Trough Forced Expiratory Volume in 1 Second (FEV1) After 2 Weeks of Treatment", "description": "Spirometry was conducted according to internationally accepted standards. The trough FEV1 was defined as the average of the FEV1 measurements taken at 23 hours 10 minutes and 23 hours 45 minutes post dose. The mixed model used baseline FEV1 and FEV1 prior to and 30 minutes post inhalation of albuterol as covariates.", "timeFrame": "Day 15 (after 2 weeks of treatment)"}], "secondaryOutcomes": [{"measure": "Trough Forced Expiratory Volume in 1 Second (FEV1) After 1 Day of Treatment", "description": "Spirometry was conducted according to internationally accepted standards. The trough FEV1 was defined as the average of the FEV1 measurements taken at 23 hours 10 minutes and 23 hours 45 minutes post dose on day 2. The mixed model used baseline FEV1 and FEV1 prior to and 30 minutes post inhalation of albuterol as covariates.", "timeFrame": "Day 2 (after 1 day of treatment)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with a diagnosis of asthma, and:\n\n  1. Receiving daily treatment with inhaled corticosteroid in a regimen that has been stable for at least a month prior to screening\n  2. Prebronchodilator forced expiratory volume in 1 second (FEV1) at screening \u226550 and \u226490% of predicted normal\n  3. An increase of \u226512% and \u2265200 mL in FEV1 over prebronchodilator value within 30 minutes after inhaling albuterol\n\nExclusion Criteria:\n\n* Smoking history \\>10 pack-years\n* Patients with a diagnosis of chronic obstructive pulmonary disease (COPD)\n* Patients with seasonal allergy whose asthma is likely to deteriorate during the study period\n* Patients who have experienced a severe asthma attack/exacerbation requiring hospitalization in the 6 months prior to screening\n* Patients who have had an intubation for a severe asthma exacerbation\n* Patients who have had an emergency room visit for an asthma attack/asthma exacerbation within 6 weeks prior to screening\n* Patients who have had a respiratory tract infection within 6 weeks prior to screening\n* Patients with concomitant pulmonary disease\n* Patients with diabetes Type I or uncontrolled diabetes Type II\n* Any patient with lung cancer or a history of lung cancer\n* Patients with a history of certain cardiovascular comorbid conditions\n* Patients who have ever received or are currently receiving omalizumab or chronic oral corticosteroid therapy\n\nOther protocol-defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigator Site", "city": "Glendale", "state": "Arizona", "zip": "85306", "country": "United States", "geoPoint": {"lat": 33.53865, "lon": -112.18599}}, {"facility": "Novartis Investigator Site", "city": "Scottsdale", "state": "Arizona", "zip": "85251", "country": "United States", "geoPoint": {"lat": 33.50921, "lon": -111.89903}}, {"facility": "Novartis Investigator Site", "city": "Encinitas", "state": "California", "zip": "92024", "country": "United States", "geoPoint": {"lat": 33.03699, "lon": -117.29198}}, {"facility": "Novartis Investigator Site", "city": "Huntington Beach", "state": "California", "zip": "92647", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "Novartis Investigator Site", "city": "Los Angeles", "state": "California", "zip": "90025", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Novartis Investigator Site", "city": "Los Angeles", "state": "California", "zip": "90048", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Novartis Investigative Site", "city": "Mission Viejo", "state": "California", "zip": "92691", "country": "United States", "geoPoint": {"lat": 33.60002, "lon": -117.672}}, {"facility": "Novartis Investigator Site", "city": "Orange", "state": "California", "zip": "92868", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -117.85311}}, {"facility": "Novartis Investigator Site", "city": "Rancho Mirage", "state": "California", "zip": "92270", "country": "United States", "geoPoint": {"lat": 33.73974, "lon": -116.41279}}, {"facility": "Novartis Investigator Site", "city": "Rolling Hills Estates", "state": "California", "zip": "90274", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -118.35813}}, {"facility": "Novartis Investigator Site", "city": "San Diego", "state": "California", "zip": "92120", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Novartis Investigator Site", "city": "San Diego", "state": "California", "zip": "92123", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Novartis Investigator Site", "city": "San Jose", "state": "California", "zip": "95117", "country": "United States", "geoPoint": {"lat": 37.33939, "lon": -121.89496}}, {"facility": "Novartis Investigator Site", "city": "Stockton", "state": "California", "zip": "95207", "country": "United States", "geoPoint": {"lat": 37.9577, "lon": -121.29078}}, {"facility": "Novartis Investigator Site", "city": "Colorado Springs", "state": "Colorado", "zip": "80907", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "Novartis Investigator Site", "city": "Denver", "state": "Colorado", "zip": "80230", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Novartis Investigator Site", "city": "Engelwood", "state": "Colorado", "zip": "80112", "country": "United States", "geoPoint": {"lat": 39.64777, "lon": -104.98776}}, {"facility": "Novartis Investigator Site", "city": "Lakewood", "state": "Colorado", "zip": "80401", "country": "United States", "geoPoint": {"lat": 39.70471, "lon": -105.08137}}, {"facility": "Novartis Investigative Site", "city": "Stamford", "state": "Connecticut", "zip": "06902", "country": "United States", "geoPoint": {"lat": 41.05343, "lon": -73.53873}}, {"facility": "Novartis Investigative Site", "city": "Waterbury", "state": "Connecticut", "zip": "06708", "country": "United States", "geoPoint": {"lat": 41.55815, "lon": -73.0515}}, {"facility": "Novartis Investigative site", "city": "Destin", "state": "Florida", "zip": "32541", "country": "United States", "geoPoint": {"lat": 30.39353, "lon": -86.49578}}, {"facility": "Novartis Investigative Site", "city": "Pensacola", "state": "Florida", "zip": "32503", "country": "United States", "geoPoint": {"lat": 30.42131, "lon": -87.21691}}, {"facility": "Novartis Investigative Site", "city": "Pensacola", "state": "Florida", "zip": "32514", "country": "United States", "geoPoint": {"lat": 30.42131, "lon": -87.21691}}, {"facility": "Novartis Investigative Site", "city": "Port Orange", "state": "Florida", "zip": "32127", "country": "United States", "geoPoint": {"lat": 29.13832, "lon": -80.99561}}, {"facility": "Novartis Investigative Site", "city": "Sarasota", "state": "Florida", "zip": "34233", "country": "United States", "geoPoint": {"lat": 27.33643, "lon": -82.53065}}, {"facility": "Novartis Investigative Site", "city": "Tamarac", "state": "Florida", "zip": "33321", "country": "United States", "geoPoint": {"lat": 26.21286, "lon": -80.24977}}, {"facility": "Novartis Investigative Site", "city": "Winter Park", "state": "Florida", "zip": "32789", "country": "United States", "geoPoint": {"lat": 28.6, "lon": -81.33924}}, {"facility": "Novartis Investigator Site", "city": "Boise", "state": "Idaho", "zip": "83704", "country": "United States", "geoPoint": {"lat": 43.6135, "lon": -116.20345}}, {"facility": "Novartis Investigator Site", "city": "Normal", "state": "Illinois", "zip": "61761", "country": "United States", "geoPoint": {"lat": 40.5142, "lon": -88.99063}}, {"facility": "Novartis Investigative Site", "city": "Springfield", "state": "Illinois", "zip": "62703", "country": "United States", "geoPoint": {"lat": 39.80172, "lon": -89.64371}}, {"facility": "Novartis Investigator Site", "city": "Overland Park", "state": "Kansas", "zip": "66210", "country": "United States", "geoPoint": {"lat": 38.98223, "lon": -94.67079}}, {"facility": "Novartis Investigative Site", "city": "Louisville", "state": "Kentucky", "zip": "40215", "country": "United States", "geoPoint": {"lat": 38.25424, "lon": -85.75941}}, {"facility": "Novartis Investigator Site", "city": "Lafayette", "state": "Louisiana", "zip": "70503", "country": "United States", "geoPoint": {"lat": 30.22409, "lon": -92.01984}}, {"facility": "Novartis Investigative Site", "city": "Baltimore", "state": "Maryland", "zip": "21236", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Novartis Investigator Site", "city": "Columbia", "state": "Maryland", "zip": "21044", "country": "United States", "geoPoint": {"lat": 39.24038, "lon": -76.83942}}, {"facility": "Novartis Investigative Site", "city": "Wheaton", "state": "Maryland", "zip": "20902", "country": "United States", "geoPoint": {"lat": 39.03983, "lon": -77.05526}}, {"facility": "Novartis Investigative Site", "city": "North Dartmouth", "state": "Massachusetts", "zip": "02747", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"facility": "Novartis Investigative Site", "city": "Minneapolis", "state": "Minnesota", "zip": "55402", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Novartis Investigator Site", "city": "Columbia", "state": "Missouri", "zip": "65203", "country": "United States", "geoPoint": {"lat": 38.95171, "lon": -92.33407}}, {"facility": "Novartis Investigator Site", "city": "Rolla", "state": "Missouri", "zip": "65401", "country": "United States", "geoPoint": {"lat": 37.95143, "lon": -91.77127}}, {"facility": "Novartis Investigator Site", "city": "St. Louis", "state": "Missouri", "zip": "63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Novartis Investigator Site", "city": "Warrensburg", "state": "Missouri", "zip": "64093", "country": "United States", "geoPoint": {"lat": 38.76279, "lon": -93.73605}}, {"facility": "Novartis Investigative Site", "city": "Missoula", "state": "Montana", "zip": "59808", "country": "United States", "geoPoint": {"lat": 46.87215, "lon": -113.994}}, {"facility": "Novartis Investigator Site", "city": "Bellevue", "state": "Nebraska", "zip": "68123", "country": "United States", "geoPoint": {"lat": 41.13667, "lon": -95.89084}}, {"facility": "Novartis Investigator Site", "city": "Boys Town", "state": "Nebraska", "zip": "68010", "country": "United States", "geoPoint": {"lat": 41.26111, "lon": -96.13196}}, {"facility": "Novartis Investigative Site", "city": "Ocean", "state": "New Jersey", "zip": "07712", "country": "United States", "geoPoint": {"lat": 39.27762, "lon": -74.5746}}, {"facility": "Novartis Investigative Site", "city": "Skillman", "state": "New Jersey", "zip": "08558", "country": "United States", "geoPoint": {"lat": 40.42011, "lon": -74.7146}}, {"facility": "Novartis Investigative Site", "city": "Charlotte", "state": "North Carolina", "zip": "28207", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Novartis Investigative Site", "city": "Raleigh", "state": "North Carolina", "zip": "27607", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "Novartis Investigator Site", "city": "Cadiz", "state": "Ohio", "zip": "43907", "country": "United States", "geoPoint": {"lat": 40.27285, "lon": -80.99676}}, {"facility": "Novartis Investigative Site", "city": "Columbus", "state": "Ohio", "zip": "43215", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "Novartis Investigative Site", "city": "Maumee", "state": "Ohio", "zip": "43537", "country": "United States", "geoPoint": {"lat": 41.56283, "lon": -83.65382}}, {"facility": "Novartis Investigator Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73103", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Novartis Investigator Site", "city": "Lake Oswego", "state": "Oregon", "zip": "97035", "country": "United States", "geoPoint": {"lat": 45.42067, "lon": -122.67065}}, {"facility": "Novartis Investigative Site", "city": "Medford", "state": "Oregon", "zip": "97504", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Novartis Investigator Site", "city": "Portland", "state": "Oregon", "zip": "97213", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "Novartis Investigative Site", "city": "Erie", "state": "Pennsylvania", "zip": "16506", "country": "United States", "geoPoint": {"lat": 42.12922, "lon": -80.08506}}, {"facility": "Novartis Investigative Site", "city": "Phoenixville", "state": "Pennsylvania", "zip": "19460", "country": "United States", "geoPoint": {"lat": 40.13038, "lon": -75.51491}}, {"facility": "Novartis Investigative Site", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15243", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Novartis Investigative Site", "city": "Upland", "state": "Pennsylvania", "zip": "19013", "country": "United States", "geoPoint": {"lat": 39.85261, "lon": -75.38269}}, {"facility": "Novartis Investigative Site", "city": "Lincoln", "state": "Rhode Island", "zip": "02865", "country": "United States", "geoPoint": {"lat": 41.92111, "lon": -71.435}}, {"facility": "Novartis Investigative Site", "city": "Charleston", "state": "South Carolina", "zip": "29414", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "Novartis Investigative site", "city": "North Charleston", "state": "South Carolina", "zip": "29406", "country": "United States", "geoPoint": {"lat": 32.85462, "lon": -79.97481}}, {"facility": "Novartis Investigator Site", "city": "Austin", "state": "Texas", "zip": "78758", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "Novartis Investigator Site", "city": "Dallas", "state": "Texas", "zip": "75231", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Novartis Investigator Site", "city": "El Paso", "state": "Texas", "zip": "79903", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}, {"facility": "Novartis Investigator Site", "city": "El Paso", "state": "Texas", "zip": "79925", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}, {"facility": "Novartis Investigator Site", "city": "Georgetown", "state": "Texas", "zip": "78628", "country": "United States", "geoPoint": {"lat": 30.63269, "lon": -97.67723}}, {"facility": "Novartis Investigator Site", "city": "North Richland Hills", "state": "Texas", "zip": "76180", "country": "United States", "geoPoint": {"lat": 32.8343, "lon": -97.2289}}, {"facility": "Novartis Investigator Site", "city": "Waco", "state": "Texas", "zip": "73712", "country": "United States", "geoPoint": {"lat": 31.54933, "lon": -97.14667}}, {"facility": "Novartis Investigator Site", "city": "Seattle", "state": "Washington", "zip": "98105", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The study consisted of a 14 day run-in period. 511 participants were randomized but only 502 participants received study drug.", "groups": [{"id": "FG000", "title": "Indacaterol 18.75 \u00b5g", "description": "Indacaterol 18.75 \u00b5g once daily in the morning via Concept1, a single-dose dry powder inhaler (SDDPI) and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, a multi-dose dry powder inhaler (MDDPI) for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study"}, {"id": "FG001", "title": "Indacaterol 37.5 \u00b5g", "description": "Indacaterol 37.5 \u00b5g once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, a MDDPI for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study."}, {"id": "FG002", "title": "Indacaterol 75 \u00b5g", "description": "Indacaterol 75 \u00b5g once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, a MDDPI for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study."}, {"id": "FG003", "title": "Indacaterol 150 \u00b5g", "description": "Indacaterol 150 \u00b5g once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, MDDPI for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study."}, {"id": "FG004", "title": "Salmeterol", "description": "Salmeterol 50 \u00b5g twice daily in the morning and in the evening via Diskus\u00ae, a multi-dose dry powder inhaler (MDDPI) and Placebo to Indacaterol once daily in the morning via Concept1, a SDDPI for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study."}, {"id": "FG005", "title": "Placebo", "description": "Placebo to Indacaterol once daily in the morning via Concept 1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, a MDDPI for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "85"}, {"groupId": "FG001", "numSubjects": "85"}, {"groupId": "FG002", "numSubjects": "84"}, {"groupId": "FG003", "numSubjects": "86"}, {"groupId": "FG004", "numSubjects": "86"}, {"groupId": "FG005", "numSubjects": "85"}]}, {"type": "Safety Set: Received Study Drug", "achievements": [{"groupId": "FG000", "numSubjects": "84"}, {"groupId": "FG001", "numSubjects": "81"}, {"groupId": "FG002", "numSubjects": "84"}, {"groupId": "FG003", "numSubjects": "85"}, {"groupId": "FG004", "numSubjects": "84"}, {"groupId": "FG005", "numSubjects": "84"}]}, {"type": "Full Analysis Set (FAS)", "achievements": [{"groupId": "FG000", "numSubjects": "84"}, {"groupId": "FG001", "comment": "2 patients (1 in 37.5 \u00b5g;1 in 75 \u00b5g group) randomized more than once and were excluded from the FAS.", "numSubjects": "80"}, {"groupId": "FG002", "numSubjects": "83"}, {"groupId": "FG003", "numSubjects": "85"}, {"groupId": "FG004", "numSubjects": "84"}, {"groupId": "FG005", "numSubjects": "84"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "83"}, {"groupId": "FG001", "numSubjects": "78"}, {"groupId": "FG002", "numSubjects": "83"}, {"groupId": "FG003", "numSubjects": "81"}, {"groupId": "FG004", "numSubjects": "78"}, {"groupId": "FG005", "numSubjects": "80"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "5"}, {"groupId": "FG004", "numSubjects": "8"}, {"groupId": "FG005", "numSubjects": "5"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "5"}, {"groupId": "FG005", "numSubjects": "1"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "3"}]}, {"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Abnormal test procedure result(s)", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Unsatisfactory therapeutic effect", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Indacaterol 18.75 \u00b5g", "description": "Indacaterol 18.75 \u00b5g once daily in the morning via Concept1, a single-dose dry powder inhaler (SDDPI) and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, a multi-dose dry powder inhaler (MDDPI) for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study"}, {"id": "BG001", "title": "Indacaterol 37.5 \u00b5g", "description": "Indacaterol 37.5 \u00b5g once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, a MDDPI for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study."}, {"id": "BG002", "title": "Indacaterol 75 \u00b5g", "description": "Indacaterol 75 \u00b5g once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, a MDDPI for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study."}, {"id": "BG003", "title": "Indacaterol 150 \u00b5g", "description": "Indacaterol 150 \u00b5g once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, MDDPI for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study."}, {"id": "BG004", "title": "Salmeterol", "description": "Salmeterol 50 \u00b5g twice daily in the morning and in the evening via Diskus\u00ae, a multi-dose dry powder inhaler (MDDPI) and Placebo to Indacaterol once daily in the morning via Concept1, a SDDPI for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study."}, {"id": "BG005", "title": "Placebo", "description": "Placebo to Indacaterol once daily in the morning via Concept 1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, a MDDPI for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study."}, {"id": "BG006", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "84"}, {"groupId": "BG001", "value": "81"}, {"groupId": "BG002", "value": "84"}, {"groupId": "BG003", "value": "85"}, {"groupId": "BG004", "value": "84"}, {"groupId": "BG005", "value": "84"}, {"groupId": "BG006", "value": "502"}]}], "measures": [{"title": "Age Continuous", "description": "All baseline measures are based on the Full Analysis Set (FAS) that includes all participants who received at least one dose of study drug.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "42.0", "spread": "14.64"}, {"groupId": "BG001", "value": "41.9", "spread": "14.96"}, {"groupId": "BG002", "value": "40.2", "spread": "14.71"}, {"groupId": "BG003", "value": "41.0", "spread": "15.20"}, {"groupId": "BG004", "value": "40.9", "spread": "14.56"}, {"groupId": "BG005", "value": "40.6", "spread": "14.17"}, {"groupId": "BG006", "value": "41.1", "spread": "14.65"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "42"}, {"groupId": "BG001", "value": "46"}, {"groupId": "BG002", "value": "49"}, {"groupId": "BG003", "value": "55"}, {"groupId": "BG004", "value": "46"}, {"groupId": "BG005", "value": "40"}, {"groupId": "BG006", "value": "278"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "42"}, {"groupId": "BG001", "value": "35"}, {"groupId": "BG002", "value": "35"}, {"groupId": "BG003", "value": "30"}, {"groupId": "BG004", "value": "38"}, {"groupId": "BG005", "value": "44"}, {"groupId": "BG006", "value": "224"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Trough Forced Expiratory Volume in 1 Second (FEV1) After 2 Weeks of Treatment", "description": "Spirometry was conducted according to internationally accepted standards. The trough FEV1 was defined as the average of the FEV1 measurements taken at 23 hours 10 minutes and 23 hours 45 minutes post dose. The mixed model used baseline FEV1 and FEV1 prior to and 30 minutes post inhalation of albuterol as covariates.", "populationDescription": "Participants from the Full Analysis Set, randomized participants who received at least one dose of study drug, who had efficacy data for this outcome measure. Missing data were imputed last observation carried forward (LOCF).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Day 15 (after 2 weeks of treatment)", "groups": [{"id": "OG000", "title": "Indacaterol 18.75 \u00b5g", "description": "Indacaterol 18.75 \u00b5g once daily in the morning via Concept1, a single-dose dry powder inhaler (SDDPI) and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, a multi-dose dry powder inhaler (MDDPI) for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study"}, {"id": "OG001", "title": "Indacaterol 37.5 \u00b5g", "description": "Indacaterol 37.5 \u00b5g once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, a MDDPI for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Indacaterol 75 \u00b5g", "description": "Indacaterol 75 \u00b5g once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, a MDDPI for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study."}, {"id": "OG003", "title": "Indacaterol 150 \u00b5g", "description": "Indacaterol 150 \u00b5g once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, MDDPI for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study."}, {"id": "OG004", "title": "Salmeterol", "description": "Salmeterol 50 \u00b5g twice daily in the morning and in the evening via Diskus\u00ae, a multi-dose dry powder inhaler (MDDPI) and Placebo to Indacaterol once daily in the morning via Concept1, a SDDPI for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study."}, {"id": "OG005", "title": "Placebo", "description": "Placebo to Indacaterol once daily in the morning via Concept 1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, a MDDPI for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "82"}, {"groupId": "OG001", "value": "77"}, {"groupId": "OG002", "value": "82"}, {"groupId": "OG003", "value": "80"}, {"groupId": "OG004", "value": "78"}, {"groupId": "OG005", "value": "81"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.50", "spread": "0.036"}, {"groupId": "OG001", "value": "2.52", "spread": "0.037"}, {"groupId": "OG002", "value": "2.59", "spread": "0.036"}, {"groupId": "OG003", "value": "2.54", "spread": "0.037"}, {"groupId": "OG004", "value": "2.54", "spread": "0.037"}, {"groupId": "OG005", "value": "2.42", "spread": "0.036"}]}]}]}, {"type": "SECONDARY", "title": "Trough Forced Expiratory Volume in 1 Second (FEV1) After 1 Day of Treatment", "description": "Spirometry was conducted according to internationally accepted standards. The trough FEV1 was defined as the average of the FEV1 measurements taken at 23 hours 10 minutes and 23 hours 45 minutes post dose on day 2. The mixed model used baseline FEV1 and FEV1 prior to and 30 minutes post inhalation of albuterol as covariates.", "populationDescription": "Participants from the Full Analysis Set, randomized participants who received at least one dose of study drug, who had efficacy data for this outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Day 2 (after 1 day of treatment)", "groups": [{"id": "OG000", "title": "Indacaterol 18.75 \u00b5g", "description": "Indacaterol 18.75 \u00b5g once daily in the morning via Concept1, a single-dose dry powder inhaler (SDDPI) and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, a multi-dose dry powder inhaler (MDDPI) for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study"}, {"id": "OG001", "title": "Indacaterol 37.5 \u00b5g", "description": "Indacaterol 37.5 \u00b5g once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, a MDDPI for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Indacaterol 75 \u00b5g", "description": "Indacaterol 75 \u00b5g once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, a MDDPI for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study."}, {"id": "OG003", "title": "Indacaterol 150 \u00b5g", "description": "Indacaterol 150 \u00b5g once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, MDDPI for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study."}, {"id": "OG004", "title": "Salmeterol", "description": "Salmeterol 50 \u00b5g twice daily in the morning and in the evening via Diskus\u00ae, a multi-dose dry powder inhaler (MDDPI) and Placebo to Indacaterol once daily in the morning via Concept1, a SDDPI for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study."}, {"id": "OG005", "title": "Placebo", "description": "Placebo to Indacaterol once daily in the morning via Concept 1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, a MDDPI for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "77"}, {"groupId": "OG002", "value": "81"}, {"groupId": "OG003", "value": "82"}, {"groupId": "OG004", "value": "79"}, {"groupId": "OG005", "value": "80"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.46", "spread": "0.026"}, {"groupId": "OG001", "value": "2.52", "spread": "0.027"}, {"groupId": "OG002", "value": "2.54", "spread": "0.026"}, {"groupId": "OG003", "value": "2.60", "spread": "0.026"}, {"groupId": "OG004", "value": "2.65", "spread": "0.027"}, {"groupId": "OG005", "value": "2.45", "spread": "0.027"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "2 weeks", "description": "Safety Population consisting of all participants who received at least one dose of study drug.", "eventGroups": [{"id": "EG000", "title": "Indacaterol 18.75 \u00b5g", "description": "Indacaterol 18.75 \u00b5g once daily in the morning via Concept1, a single-dose dry powder inhaler (SDDPI) and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, a multi-dose dry powder inhaler (MDDPI) for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study", "seriousNumAffected": 0, "seriousNumAtRisk": 84, "otherNumAffected": 4, "otherNumAtRisk": 84}, {"id": "EG001", "title": "Indacaterol 37.5 \u00b5g", "description": "Indacaterol 37.5 \u00b5g once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, a MDDPI for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study.", "seriousNumAffected": 0, "seriousNumAtRisk": 81, "otherNumAffected": 2, "otherNumAtRisk": 81}, {"id": "EG002", "title": "Indacaterol 75 \u00b5g", "description": "Indacaterol 75 \u00b5g once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, a MDDPI for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study.", "seriousNumAffected": 0, "seriousNumAtRisk": 84, "otherNumAffected": 12, "otherNumAtRisk": 84}, {"id": "EG003", "title": "Indacaterol 150 \u00b5g", "description": "Indacaterol 150 \u00b5g once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, MDDPI for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study.", "seriousNumAffected": 1, "seriousNumAtRisk": 85, "otherNumAffected": 7, "otherNumAtRisk": 85}, {"id": "EG004", "title": "Salmeterol", "description": "Salmeterol 50 \u00b5g twice daily in the morning and in the evening via Diskus\u00ae, a multi-dose dry powder inhaler (MDDPI) and Placebo to Indacaterol once daily in the morning via Concept1, a SDDPI for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study.", "seriousNumAffected": 0, "seriousNumAtRisk": 84, "otherNumAffected": 5, "otherNumAtRisk": 84}, {"id": "EG005", "title": "Placebo", "description": "Placebo to Indacaterol once daily in the morning via Concept 1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus\u00ae, a MDDPI for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) albuterol was available for rescue use throughout the study.", "seriousNumAffected": 0, "seriousNumAtRisk": 84, "otherNumAffected": 4, "otherNumAtRisk": 84}], "seriousEvents": [{"term": "Substance abuse", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 81}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 85}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 84}]}], "otherEvents": [{"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 84}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 81}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 84}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 85}, {"groupId": "EG004", "numAffected": 4, "numAtRisk": 84}, {"groupId": "EG005", "numAffected": 4, "numAtRisk": 84}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 84}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 81}, {"groupId": "EG002", "numAffected": 8, "numAtRisk": 84}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 85}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 84}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 84}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068299", "term": "Salmeterol Xinafoate"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M3767", "name": "Albuterol", "relevance": "LOW"}, {"id": "M251", "name": "Salmeterol Xinafoate", "asFound": "Metabolism", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}